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Abstract 
BACKGROUND: Patients go without pacemaker, defibrillator, and cardiac resynchronization 
therapies (devices) each year due to the prohibitive costs of devices. 
 
OBJECTIVE: We sought to examine data available from studies regarding contemporary risks of 
reused devices in comparison with new devices. 
 
METHODS: We searched online indexing sites to identify recent studies.  Peer-reviewed manuscripts 
reporting infection, malfunction, premature battery depletion, and device related death with reused 
devices were included. The primary study outcome was the composite risk of infection, malfunction, 
premature battery depletion, and death.  Secondary outcomes were the individual risks. 
 
RESULTS: Nine observational studies (published 2009 – 2017) were identified totaling 2 302 devices 
(2 017 pacemakers, 285 defibrillators).  Five controlled trials were included in meta-analysis (2 114 
devices; 1 258 new versus 856 reused).  All device reuse protocols employed interrogation to 
confirm longevity and functionality, disinfectant therapy and, usually, additional biocidal agents, 
packaging and ethylene oxide gas sterilization. Demographic characteristics, indications for pacing, 
and median follow-up were similar.  There were no device-related deaths reported and no 
statistically significant difference in risk between new versus reused devices for the primary 
outcome (2.23% versus 3.86% respectively, p = 0.807, OR = 0.76).  There were no significant 
differences seen in the secondary outcomes for the individual risks of infection, malfunction, and 
premature battery depletion. 
  
CONCLUSIONS: Device reuse utilizing modern protocols did not significantly increase risk of 
infection, malfunction, premature battery depletion or device related death in observational studies.  
This data provides rationale for proceeding with a prospective multi-center non-inferiority 
randomized control trial. 
 
 
KEYWORDS:  Pacemaker reuse, defibrillator reuse, cardiac resynchronization therapy reuse, 
pacemaker recycling, defibrillator recycling, cardiac resynchronization therapy recycling  
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BACKGROUND 
Major progress has been made in the management of pathologic bradycardia, ventricular 
tachycardia, and systolic congestive heart failure, utilizing implantable pacemaker, defibrillator, 
and/or cardiac resynchronization therapy (CRT), respectively.1,2  However, while these advanced 
therapies have become commonplace in high income nations, they are rarely available in most low 
and middle-income nations.3,4  Annual pacemaker implantation rates of > 700 per million are seen in 
France, Sweden, and the United States of America (USA), in stark contrast to rates of < 7 per million 
in Indonesia, Pakistan, and the Philippines.3  Meanwhile, Germany, the Netherlands, and the USA 
exhibit annual defibrillator implantation rates of > 200 per million whereas they remain < 2 per 
million in Bangladesh, India, and Peru.3  The greatest barrier for device implantations cited by 90% of 
physicians from underserved regions is the prohibitive cost of such medical devices for most of their 
patients.5  Accordingly, many clinicians have undertaken studies examining the safety and efficacy of 
pacemaker reuse and, as a result, the protocols for retrieval, resterilization, and reimplantation of 
pacemakers have been greatly refined over the last four decades.6 - 11 
In light of recently published controlled trials, we sought to systematically review the contemporary 
data made available in the last decade regarding the safety and efficacy of pacemaker, defibrillator, 
and CRT (herein termed “device”) reuse and compare to new device use in underserved nations. 
 
METHODS 
This study was performed in accordance with the MOOSE Guidelines for Meta-Analyses and 
Systematic Reviews of Observational Studies.12 
Search Strategy 
Two study investigators (BS, SKS) independently searched the medical literature to identify all 
relevant device studies from January 1st, 2008 until December 31st, 2017 using PubMed/MEDLINE 
(United States National Library of Medicine, Bethesda, MD), EMBASE, the Cochrane Database of 
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Systematic Reviews, and Google Scholar.  We focused upon studies involving humans and utilized 
the keywords; “pacemaker”, “defibrillator”, “cardiac resynchronization therapy” or “bi-ventricular 
pacing” coupled with “reused”, “reutilized”, or “recycled” as our search terms.  Clinicaltrials.gov was 
searched to identify relevant ongoing or unpublished trials.  In addition, the reference lists of 
selected trials and reviews were hand searched for potentially relevant citations. 
Study Selection 
A study was included in the pooled analysis if it was published in a peer reviewed journal and 
reported the incidence of infection, malfunction, premature battery depletion, and device related 
death following device reuse.  Two investigators (BS, SKS) abstracted and collated comparable data 
from each study in a standardized manner.  Baseline demographic, clinical, and procedural 
characteristics including procurement source, sterilization technique, antibiotic use, follow-up 
duration, and device related complications were recorded.  Additionally, a study was included in 
subsequent meta-analysis if the aforementioned outcomes in a new device population (control 
group) were compared to a reused device population (study group). 
Study Outcomes 
The primary study outcome was set as the composite risk of device infection, device malfunction, 
premature battery depletion, and device related death.  Secondary study outcomes included the 
individual risks of infection, malfunction, premature battery depletion, and device related death.  
Device infection was defined as an early or late local or systemic device related infection warranting 
device explantation during the study period.  Device malfunction was defined as a defect in the 
structural or electrical integrity of the pulse generator compromising device function.  Premature 
battery depletion was defined as unexpected battery failure prior to the longevity estimation 
determined at implantation.  Only trials with > 2 years of median follow-up were included in the 
secondary meta-analysis of premature battery depletion to minimize the risk of under-detecting 
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adverse events (beta error).  Device-related death was defined as death attributable to device 
related infection, malfunction, or premature battery depletion as reported by the study authors. 
Statistical Methods 
Categorical variables were expressed as percentages and continuous variables were expressed as 
means with standard deviations.  Non-normally distributed variables were summarized as medians 
with inter-quartile (IQR) ranges.  All raw data on the primary outcome were pooled and compared 
between groups using mixed-effect generalized linear models with study as the random effect.  Data 
from studies that included comparison between reused device implantation (study group) and new 
device implantation (control group) were combined to estimate the pooled effect using random-
effect meta-analyses.   Odds Ratios [ORs] of study outcomes and their 95% Confidence Intervals (CIs) 
comparing reused devices with new devices were calculated using the DerSimonian and Laird 
method.13  Studies that did not report an event were not included in the meta-analysis for that 
relevant secondary outcome, and for studies with zero events in one arm, a 0.5 constant continuity 
correction was used.  To assess the potential risk of introducing bias with this approach, sensitivity 
analyses were performed by adding different constants instead of 0.5.14  Heterogeneity among trials 
was assessed with the Higgins and Thompson I2 index.15  I2 can be interpreted as the percentage of 
variability caused by heterogeneity between studies.  The potential for significant small study effects 
was ascertained utilizing Egger’s test.16  The potential for reporting publication bias was assessed 
graphically using a funnel plot generated by plotting the standard error versus the DerSimonian and 
Laird log OR for each controlled study.17  The analyses are presented as point estimates, and 95% 
confidence intervals are shown within brackets.  All tests were 2-tailed, and a p value of < 0.05 was 
considered statistically significant.  Meta-analysis was conducted using the meta-analysis module in 
Stata 14 (Stata Statistical Software: Release 14. StataCorp LP, College Station, TX). 
Institutional Review Board approval was not required for this study as all primary information 
included in analysis has been made publicly available in peer reviewed medical journals. 
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RESULTS 
Study Selection and Study Patients 
An on-line search using the key search terms identified 172 articles (see Figure 1).  Detailed review 
ascertained 10 relevant clinical studies published between 2009 and 2017 involving device reuse.18 - 
27  We excluded one case series18 due to duplication of data in a larger subsequent trial publication24 
leaving 9 studies totaling 2 302 devices as summated in the pooled analysis (see Figure 2 and Table 
1).  The demographic characteristics regarding age, gender, and indication for pacing therapy (when 
applicable) were similar between the new device and reused device populations (see Table 2).   
Study Designs, Protocols, and Procedures 
All studies were single center, un-blinded, non-randomized, retrospective or ambispective (initially 
retrospective but then converted to prospective methodology during the study period) in nature.  
Specified permission was obtained from patients (ante-mortem) or patients’ families (post-mortem) 
for device donation for reuse.  All studies clearly stated that written informed consent was obtained 
from recipients prior to device implantation or reimplantation with emphasis placed on the potential 
hazards unique to device reuse. 
Every study described interrogation and reprogramming of donated devices.  Interrogation was 
usually undertaken prior to resterilization to confirm software and hardware functionality and 
ensure adequate device longevity (stipulated by most as > 3 years or > 4 years).  Devices subject to 
manufacturer recall or on advisory were excluded.  Pacemakers were reprogrammed to “pacing off” 
or pacing with minimal voltage output.  Defibrillators were programmed to not pace or pace with 
minimal voltage output and ventricular tachycardia/ventricular fibrillation detection and therapy, as 
well as auditory or vibratory alerts, were programmed “off”.  Programmable identifiable patient data 
(patient’s name, physician, medical center, date of initial implant) was routinely erased prior to 
shipping. 
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The resterilization protocols employed in the studies reviewed were similar in approach.  Initially, 
donated devices were inspected for signs of external damage and tested for lead port set screw 
malfunction precluding reuse.  They were then cleaned with either pipe cleaners or soft tip brushes 
to remove debris from the surface and the lead ports.  All but one study utilized 3% hydrogen 
peroxide and/or an alcohol solution (isopropyl alcohol or 70% ethanol) as a disinfectant.  All but two 
studies made use of an additional biocidal measure (five used an enzymatic detergent, one used 
iodine, and one used benzalkonium chloride).  As the final step, all study protocols packaged devices 
in gas permeable envelopes and utilized ethylene oxide gas sterilization.  Three studies also 
indicated that ethylene oxide gas sterilization was repeated at 3 to 6 month intervals if the device 
remained unused in the interim. 
The implantation of both new and reused devices was undertaken at the same medical center in the 
recipients’ underserved country by an electrophysiologist, interventional cardiologist, or trained 
general cardiologist, for American College of Cardiology/American Heart Association/Heart Rhythm 
Society and/or European Society of Cardiology class I or class II guideline directed indications.1,2  
Peri-operative antibiotics were used with consistent application for both new and reused devices in 
all but one uncontrolled study where antibiotics were not employed.20 
Pooled analysis 
The nine studies of contemporary interest included 2 302 devices divided between 1 258 new 
devices and 1 044 reused devices (Table 1 and Table 2).  Most devices were single or dual-chamber 
pacemakers (1 748), however, CRT-pacemakers (269), implantable cardioverter-defibrillators (202), 
and CRT-defibrillators (83) were also included.  The baseline demographics (age, gender, and pacing 
indication) between the new device and reused device groups were similar.  In the 2 071 devices 
with a specific clinical indication for pacing stipulated, the most common diagnosis was second or 
third degree AV block (61.8%) followed by sinus node dysfunction (20.6%) followed by requirement 
for cardiac resynchronization therapy (17.6%).  
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In the analysis of the pooled data (Table 3), the overall risk of the composite primary outcome was 
not significantly different in the new device population (2.2%) versus the reused device population 
(3.2%, p = 0.419).  Tabulation of each of the sub-categorized secondary outcomes revealed no 
differences in the risks for device infection (1.8% new versus 1.7% reused), device malfunction (0.0% 
new versus 0.2% reused), and premature battery depletion (0.8% new versus 1.7% reused).  Of note, 
there were no device related deaths reported. 
Meta-analysis 
We included data derived from the five controlled trials23 – 27 totaling 2 114 devices in further 
analysis comparing the primary and secondary outcomes of patients with new devices (1 258) to 
reused devices (856).  The median follow-up and interquartile range (IQR) was 2.2 years (1.0 – 2.8 
years) for the new device group and 2.6 years (1.4 – 3.5 years) for the reused device group.  The 
Egger’s test for small study effects (p = 0.966) proved nonsignificant (not shown) while the funnel 
plot did not indicate publication bias (see Figure 3). 
Primary Outcome 
All five controlled trials were eligible for inclusion in the comparative assessment of the primary 
outcome (composite of device infection, device malfunction, premature battery depletion, and 
device related death).  Meta-analysis revealed no significant difference in the primary outcome seen 
between the new device (control) group versus the reused device (study) group (2.23% versus 
3.86%, P = 0.807, OR = 0.76 [95% CI: 0.45 to 1.28] see Figure 4). 
Secondary Outcomes 
Four trials totaling 1 988 devices were included in the assessment of infection risk comparing new 
devices (1 195) to reused devices (793) and no significant difference was seen (1.9% versus 2.3%, p = 
0.785, OR = 1.09 [95% CI: 0.58 to 2.07] see Figure 5A).  Two trials totaling 815 devices were included 
in the assessment of malfunction risk comparing new devices (409) to reused devices (406) with no 
significant difference shown (0.0% versus 0.5%, p = 0.319, OR = 0.32 [95% CI: 0.03 to 3.05] see Figure 
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5B).  Three trials totaling 1 015 devices were included in the assessment of premature battery 
depletion risk comparing new devices (518) with a median follow-up of 3.8 years (IQR: 2.2 – 6.0 
years) to reused devices (497) with a median follow-up of 3.5 years (IQR: 2.2 – 5.2 years), and again 
no significant difference was demonstrated (1.0% versus 2.6%, p = 0.084, OR = 0.43 [95% CI: 0.16 to 
1.12]). 
 
DISCUSSION 
Unmet Global Health Need 
There is an urgent need to pursue practical solutions to reduce the global burden of cardiovascular 
disease which is foremost of the chronic illnesses that have supplanted infectious diseases as the 
leading cause of death in most low and middle-income nations.28  An estimated 1.7 million cardiac 
rhythm device implantations are undertaken worldwide each year.4  However, it is conservatively 
estimated that more than 1 million patients who require such device therapy go without treatment 
annually.4  Implanting physicians in underserved nations cite device expense as the single greatest 
barrier to device therapy in their regions.5  This viewpoint is not surprising as the cost for a new 
pacemaker pulse generator (approximately $2,500 - $8,000 US dollars) or a new defibrillator 
generator (approximately $10,000 - $18,000 US dollars) by itself represents a prohibitive obstacle for 
most people in low and middle-income nations.  By contrast, the reported estimated cost of 
collecting, interrogating, reprocessing, and distributing such devices is $75 - 100 US dollars per 
device, albeit this is contingent upon volunteer assistance at a variety of levels.29 – 30  As a 
consequence, governmental authorities, hospital administrators, physicians, and their patients, in 
several underserved nations have proven receptive to assisting clinical studies examining the safety 
and efficacy of reusing devices, most of which were donated by those in high income nations in 
Europe and the USA where current laws prevent their reuse in humans. 
Reuse Concerns & Regulatory Climate 
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Pacemaker reuse has been the subject of clinical study for more than forty years now.  In fact, a prior 
systematic review and meta-analysis encompassing 18 studies (completed between 1974 – 2008) 
that included 5 controlled trials (completed between 1987 – 2001) demonstrated a generally 
favorable safety profile.11  However, a five-fold increase in pacemaker malfunction (often related to 
problems with the set screw and grommet in the lead port or premature battery depletion) in 
reused pacemakers was observed in that analysis.11  Additionally, larger and more complex cardiac 
rhythm management devices (defibrillators, CRT-pacemakers, and CRT-defibrillators) were not yet in 
common clinical practice and thus not included in reuse studies of that era.  Importantly, there have 
been no subsequent alterations in the restrictive USA, Canadian, and European Union laws 
regulating what manufacturers label as “single use devices” nor medical professional societal 
recommendations to assist high income nations with such humanitarian efforts in low and middle-
income nations.31-33  This regulatory climate persists even though 87% of both device patients and 
device physicians surveyed in the United States are willing to donate their devices post-mortem to 
help indigent patients in other nations.34,35  In fact, the majority of American device patients in the 
modern era die with pacemakers and defibrillators that are functional and have > 7 years battery 
longevity on average.36  Unfortunately, such devices are much more likely to be discarded by funeral 
homes and crematoriums as “medical waste”.37  Consequently, the task of transforming our first 
world medical waste into life saving device therapy has to date fallen upon ad hoc medical volunteer 
initiatives and international charitable organizations such as Stimubanque (Paris, France), World 
Medical Relief (Detroit, USA), and Pace4Life (London, United Kingdom). 
Contemporary Trials – New Lessons 
Our systematic review and meta-analysis of recent controlled trials encompassed studies 
undertaken in seven distinct countries spanning four continents utilizing 2 302 devices (Figure 2).  
Despite prominent differences in medical personnel, health care environments, patients, cultural 
and geographic settings, they yielded similar results, and support the safety and efficacy of device 
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reuse with regards to the composite primary outcome (overall risk < 4%) as well as each of the 
individual  secondary outcomes of infection, malfunction, premature battery depletion, and device 
related death.  Importantly, unlike the previous systematic review by Baman et al11, the current 
analysis included studies in which more complex devices (CRT and implantable cardioverter-
defibrillators) were used.20,22,25,27  The consequences of defibrillator malfunction can extend beyond 
a lack of pacing if shock therapy is also required.  In this regard, the four studies included did not 
reveal malfunction which would render defibrillators ineffective or harmful.  We believe that the 
increased rate of device malfunction noted in the prior pooled analysis11 has now abated due to the 
practice of inspection and testing of the hardware with particular scrutiny dedicated to ensuring the 
functionality of the set screws by reprocessing centers in addition to the adoption of improved 
lithium battery technologies by manufacturers. 
Limitations 
The main limitation in our systematic review and meta-analysis lies in our reliance upon data from 
unblinded, non-randomized, retrospective or ambispective, single center trials.  Thusly, we readily 
acknowledge that retrospective studies predispose to selection bias.  Due to the medico-legal 
constraints on devices currently labelled as “single use only”, and the ethical requirement to inform 
patients of the possible hazards of device reuse, it is likely not feasible to undertake a double-blind 
multi-center randomized control trial of this nature in high income nations where device cost is not a 
barrier to receiving therapy.  Accordingly, a concerted effort is underway to secure operational 
funding, donation of new leads, and the standardized clinical care necessary to pursue an adequately 
powered prospective multi-center randomized control trial in a handful of underserved nations.30  If 
such a study confirms the  non-inferiority of reused devices, securing large scale lead availability 
beyond that provided by charitable partners remains a limitation.  New pacing and defibrillator leads 
(approximate cost $200 - $1,500 US dollars) remain a formidable expense for indigent patients and 
collaboration with industry may be required to fill this void. 
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Secondly, a handful of different device manufacturers were encompassed in the studies examined.  
Hence, it is possible that a set of studies with a markedly different distribution of manufacturers may 
have yielded different results with regards to the risks of device malfunction and/or premature 
battery depletion.   
Finally, given the low adverse event rates seen overall in the studies pooled here (reflected in part by 
the wide confidence intervals reported), it is possible that a much larger analysis may, in fact, better 
detect small but significant differences that would otherwise be undiscernible.  
 
CONCLUSIONS 
Major technological advances in medical care provide new opportunities to benefit all patients that 
need such therapies.  Contemporary device reuse utilizing modern protocols did not significantly 
increase risk of infection, malfunction, premature battery depletion or device related death in 
observational studies.  It is our belief that this data helps provide the rationale for an adequately 
powered prospective multi-center non-inferiority randomized control trial of this financially 
inexpensive but clinically invaluable resource. 
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FIGURE AND TABLE LEGENDS 
 
Figure 1.  Flow Diagram of Studies Selected for Pooled Analysis and Meta-Analysis. 
 
 
 
Figure 2.  World Wide Map of Nations Participating in Contemporary Trials of Device Reuse:  Nine 
clinical trials totaling 2 302 devices examined the safety & efficacy of device reuse in seven nations 
from 2000 to 2015.  The blue color scale correlates with the total device volume in each nation. 
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Figure 3.  Funnel Plot for Publication Bias.  This graphic plot indicates no significant publication bias 
in the five trials included in the meta-analysis of the primary outcome. 
 
 
 
 
 
 
 
 
 
Figure 4.  Forest Plot of Primary Outcome in Trials of New Devices versus Reused Devices:  The 
primary outcome was the composite risk of device infection, device malfunction, premature battery 
depletion, and device related death. 
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Figures 5A & 5B.  Forest Plots of Secondary Outcomes in Trials of New Devices versus Reused 
Devices: A) Risk of device infection, B) Risk of device malfunction. 
 
 
 
 
 
 
 
 
Table 1: Characteristics of Recent Uncontrolled & Controlled Trials 
 
Study Study 
Country 
Publication 
Year 
Donation Type Study 
Period 
Reused 
Devices  
New 
Devices  
Baman et al Philippines 2009 Post-mortem 2008 12 - 
Hasan et al Nicaragua 2011 Ante-mortem 2003 - 2011 17 - 
Kantharia et 
al 
India 2012 Post-mortem 2004 - 2012 53 - 
Pavri et al India 2012 Ante/Post-
mortem 
2002 - 2011 106 - 
Nava et al Mexico 2013 Post-mortem 2000 - 2010 307 296 
Feng et al China 2014 Ante-mortem† 2007 - 2012 99  113 
Jama et al South 
Africa 
2015 Post-mortem 2003 - 2013 63 63 
Sosdean et al Romania 2015 Ante/Post-
mortem 
2000 - 2014 127 159 
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Selvaraj et al India 2017 Ante/Post-
mortem 
2010 - 2015 260 627 
Total Devices (Pacemaker, Defibrillator, CRT-D or CRT-P) in Trials: 2302 1044 1258 
 
 
Table 1: Characteristics of Recent Uncontrolled & Controlled Trials: Nine clinical studies published 
between 2009 – 2017 were included in analysis.  CRT-D: cardiac resynchronization therapy – 
defibrillator, CRT-P: cardiac resynchronization therapy - pacemaker, †99 subjects undergoing 
explantation consented to reuse of the same device for re-implantation.  
 
Table 2: Baseline Demographics of Recent Trial Subjects in Analysis 
Study Mean Age ± SD (Years) Male Number (%) *Primary Pacing Indications: 
 AV Block (%)/Sinus Node Dysfunction (%)/ CRT 
(%) 
 Reused New Reused New Reused (900) New (1171) 
Baman et al 62.0 ± 
10.0 
- 6 (50.0) - 10/2/0 - 
Hasan et al 42.1 ± 
20.3 
- 9 (52.9) - 8/3/1 - 
Kantharia et 
al 
64.0 ± 
10.0 
- 25 (47.2) - 27/26/0 - 
Pavri et al 52.6 ± 
13.8 
- 88 (83.0) - 0/0/15 - 
Nava et al 59.9 ± 
20.6 
60.4 ±19.1 158 
(51.5) 
158 
(53.4) 
236/65/0 204/82/0 
Feng et al 63.7 ± 
15.0 
65.0 ± 14.3 62 (62.6) 84 (74.3) 48/44/5 62/42/7 
Jama et al 69.7 ± 
17.3 
68.6 ± 16.4 34 (54.0) 34 (54.0) 38/9/0 43/4/0 
Sosdean et al 61.7 ± 
10.1 
61.0 ± 9.4 19 (15.0) 25 (15.7) 0/0/127 0/0/159 
Selvaraj et al 62.3 ± 
12.9 
54. 7 ± 
17.1 
108 (48) 272 
(50.8) 
193/31/12 411/119/38 
Mean or 
Total 
60.5 58.5 509 
(48.8) 
573 
(45.6) 
560 (62.2)/180 (20.0)/ 
160 (17.8) 
720 (61.5)/247 (21.1)/ 
204 (17.4) 
Table 2: Baseline Demographics of Recent Trial Subjects in Analysis: Mean age, male proportion, 
and primary pacing indications in each study.  *Patients with unspecified or less common pacing 
indication or with defibrillator indication without primary pacing indication not included. CRT: 
cardiac resynchronization therapy. 
 
 21 
 
 
This article is protected by copyright. All rights reserved. 
21 
 
 
Table 3: Primary & Secondary Outcomes of Recent Uncontrolled & Controlled Trials 
 
Study Primary Composite Outcome 
(%) 
Infection (%) Malfunction 
(%) 
Early Depletion 
(%) 
 Reused (1044) New (1258) Reused New Reused New Reused New 
Baman et al 0 - 0 - 0 - N/A - 
Hasan et al 0 - 0 - 0 - 0 - 
Kantharia et 
al 
0 - 0 - 0 - 0 - 
Pavri et al 0 - 0 - 0 - 0 - 
Nava et al 22 16 10 11 1 0 11 5 
Feng et al 4 2 3 2 1 0 0 0 
Jama et al 1 0 0 0 0 0 1 0 
Sosdean et al 6 7 5 7 0 0 1 0 
Selvaraj et al 0 3 0 3 0 0 N/A N/A 
Total (%) 33 (3.16) 28 (2.23) 18 
(1.72) 
23 
(1.83) 
2 (0.19) 0 (0) 13 (1.66) 5 (0.79) 
 
Table 3: Primary and Secondary Outcomes in Recent Uncontrolled & Controlled Trials: The primary 
outcome the composite risk of device infection, device malfunction, and premature battery 
depletion.  No device related deaths were reported.  N/A – data outcome was non-applicable as 
follow-up duration (limited to 2 – 6 months) was deemed inadequate to evaluate for premature 
battery depletion. 
 
